Drug Profile
Research programme: anticancer combination therapeutics - Novartis/EPIRUS
Latest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator CombinatoRx; Novartis
- Developer EPIRUS Biopharmaceuticals; Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
- 02 May 2013 Early research is ongoing in USA